Mass spectrometric and kinetics characterization of modified species of Growth Hormone Releasing Hexapeptide generated under thermal stress in different pH and buffers

Santana, Héctor; Espinosa, Luis Ariel; Sánchez, Aniel; Álvarez, Analía; Besada, Vladimir; González, Luis Javier

doi:10.1016/j.jpba.2020.113776

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formaldehyde is frequently used to produce whole inactivated vaccines, as it can cause protein, ribonucleic acid, or deoxyribonucleic cross-linking, either homogeneously or heterogeneously. In view of the high reactivity of formaldehyde, small changes in incubation time, pH, temperature, and concentration can affect the degree of antigen modification [ 40 , 41 ]. Raie Jadidi et al found that the process for treating influenza virus with formalin could be optimized with small changes, including changes in the concentration and incubation time [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

An Optimized FI-RSV Vaccine Effectively Protects Cotton Rats and BALB/c Mice without Causing Enhanced Respiratory Disease

Lin

Zhang

Yin

et al. 2022

Viruses

View full text Add to dashboard Cite

Background: Despite considerable efforts toward vaccine development in past decades, no effective vaccines against respiratory syncytial virus (RSV) are available. Recently, we showed that an optimized formalin concentration can preserve prefusion protein (pre-F) on RSV-infected cells and protect mice against RSV infection without causing enhanced respiratory disease (ERD). Here, we sought to further stabilize pre-F on RSV virions by optimizing the production of FI-RSV. Methods: Freshly produced RSV virions were treated with formalin under different concentrations to obtained an opti-FI-RSV vaccine with high pre-F level. Immunogenicity and safety of opti-FI-RSV were evaluated in Balb/c mice and cotton rats. Results: Using 0.0156–0.1778% formalin, we successfully preserved pre-F on virions. This opti-FI-RSV exhibited improved immunogenicity and efficacy without causing ERD. Surprisingly, opti-FI-RSV, with a pre-F-dominant immunogen, still caused ERD after immunization with a suboptimal dose or when the neutralizing antibody titers declined. ERD was avoided by coadministering opti-FI-RSV with CpG + MPLA adjuvant, which subsequently induced a Th1-biasing immune response and, more importantly, significantly improved antibody avidity. Conclusions: Our study provides a new method to obtain a novel FI-RSV vaccine with a high pre-F level and may provide a reference for developing other inactivated vaccines. Our findings also emphasize that appropriate adjuvants are critical for nonreplicating vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%